Cargando…

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

Background: Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It is characterized by the accumulation of clonal malignant plasma cells within the bone marrow. The development of drug resistance remains a major problem for effective treatment of MM. Understand the m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gourzones, Claire, Bellanger, Céline, Lamure, Sylvain, Gadacha, Ouissem Karmous, De Paco, Elvira Garcia, Vincent, Laure, Cartron, Guillaume, Klein, Bernard, Moreaux, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521290/ https://www.ncbi.nlm.nih.gov/pubmed/30925767 http://dx.doi.org/10.3390/cancers11040439

Ejemplares similares

Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
por: Herviou, Laurie, et al.
Publicado: (2021)

Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma
por: Devin, Julie, et al.
Publicado: (2022)

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
por: Caraux, Anouk, et al.
Publicado: (2012)

Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma
por: Gourzones, Claire, et al.
Publicado: (2019)

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
por: Hassen, Wafa, et al.
Publicado: (2014)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
por: Kassambara, Alboukadel, et al.
Publicado: (2014)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019)

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Retracted: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment
por: Lamure, Sylvain, et al.
Publicado: (2020)

DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets
por: Gabellier, Ludovic, et al.
Publicado: (2020)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2022)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma
por: Moreaux, Jerome
Publicado: (2014)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
por: Bruyer, Angelique, et al.
Publicado: (2018)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
por: Farag, Sarah, et al.
Publicado: (2022)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

Differential effects of lenalidomide during plasma cell differentiation
por: Jourdan, Michel, et al.
Publicado: (2016)

Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells
por: Xiong, Ting, et al.
Publicado: (2015)

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan
por: Håland, Erling, et al.
Publicado: (2021)

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
por: Viziteu, Elena, et al.
Publicado: (2016)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
por: Ovejero, Sara, et al.
Publicado: (2021)

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
por: Viziteu, E, et al.
Publicado: (2017)

C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients
por: Mallard, Joris, et al.
Publicado: (2019)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma
por: Xie, Jiayin, et al.
Publicado: (2014)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6i06166277g6alitb7lfd0rv13